Business Wire

LILIUM-OTSUKA-CO.,-LTD.

2.10.2015 14:01:58 CEST | Business Wire | Pressemeddelelse

Del
Lilium Otsuka: Lilium® α-200, a Continuous Urine Volume Sensor, Will Be Launched in Japan

Lilium Otsuka Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. will begin selling the Lilium® α-200, a continuous, non-invasive bladder urine volume sensor, on November 2, 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151002005301/en/

This product makes it possible to continuously monitor urination schedules in patients who have lost the urge to urinate. It is anticipated that this will alleviate the need for daily, lifestyle-restricting indwelling bladder (“Foley”) catheters and the anxiety of incontinence.

Problems with urination independence and control are known to determine the ability of patients to return home from the hospital, and impose a heavy burden on nursing and caregiving services. Lilium α-200 is expected to greatly contribute to the improvement of patient quality of life, and to reduce labor and improve the efficacy of those engaged in nursing and caregiving. Further, Lilium Otsuka expects to make a significant contribution to holistic treatments which impact the dignity of patients.

“For patients with loss of urge or urinary difficulty, the beauty of this product lies in its ability to accurately monitor the size of the bladder (a measure of volume of urine retained in the bladder) and the ability to schedule bathroom trips or self-catheterization.” said Dr. Osamu Yokoyama M.D., Ph.D., president of the Japanese Continence Society and professor on the Faculty of Medical Sciences, the University of Fukui, “As the Japanese Continence Society initiates a certified physician system next year to begin training doctors who can professionally manage continence care, this device is thought to provide a good method to support discharge of patients to their homes.”

About Lilium Otsuka

Lilium Otsuka is a subsidiary company of Otsuka Holdings Co., Ltd. (TOKYO:4578) established in Kanagawa, Japan. It is dedicated to standardizing the practice of measuring urinary volume as a “fifth vital sign” through developing innovative bladder health products.

About Lilium ® α-200

Lilium® α-200 is an innovative, hand-held urine volume sensor which works with two AA batteries. The device measures not only bladder urine residual but also provides alerts on appropriate timing for clean-intermittent catheterization through continuous urine volume measurement.

Contact:

Keiko Yoshimura
Lilium Otsuka Co., Ltd.
+81-42-704-3822
lilium_info@otsuka.jp
Website link: http://lilium200.jp/index-en.html

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

AIT Worldwide Logistics Welcomes Justin Kosslyn as Chief Digital and Technology Officer13.7.2026 17:02:00 CEST | Press release

Proven leader with Google experience to advance company’s AI-powered digital transformation Supply chain solutions leader AIT Worldwide Logistics has hired Justin Kosslyn, a tenured software development executive, as its chief digital and technology officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713269550/en/ Justin Kosslyn will lead an accelerating digital transformation at AIT Worldwide Logistics, unifying a vastly diverse array of shippers and partners across the globe. In the newly created role, Kosslyn will report directly to President and Chief Operating Officer, Keith Tholan, and lead the company’s global technology strategy, continuing to implement AIT’s existing program while accelerating the next generation of integrated digital, data, AI and customer-facing systems across the organization. “With a history of delivering for companies at the center of global technology and innovation, Justin brings the k

Labaton Keller Sucharow LLP Launches Corporate Accountability & Governance Task Force13.7.2026 16:46:00 CEST | Press release

Labaton Keller Sucharow LLP is pleased to announce the launch of its new Corporate Accountability & Governance Task Force, designed to help institutional investors advance corporate accountability while pursuing meaningful shareholder recoveries. Created in response to the increasing needs of our clients, the Task Force will provide clients with strategic advice on opportunities to drive positive corporate change through securities and shareholder litigation. This initiative reflects the Firm’s longstanding commitment to protecting investor interests while promoting responsible corporate conduct. Labaton partners with institutional investor clients to pursue cases that not only seek financial recovery but also encourage meaningful corporate reforms and reinforce sound governance practices. The Task Force is chaired by Partners Carol C. Villegas and Domenico “Nico” Minerva, who have led some of the Firm's most significant matters involving corporate accountability and governance reform.

FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release

The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio

Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release

Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye